The effectiveness of intravitreal dexamethasone implant in macular edema related to retinal vein occlusions

Basit Öğe Kaydı
dc.authorscopusid56884628500
dc.authorscopusid9736176600
dc.authorscopusid55365755200
dc.authorscopusid56321458200
dc.authorscopusid6602300890
dc.contributor.authorOzelce R.
dc.contributor.authorGurlu V.
dc.contributor.authorOzal S.A.
dc.contributor.authorGuçlu H.
dc.contributor.authorEsgin H.
dc.date.accessioned2024-06-12T10:28:43Z
dc.date.available2024-06-12T10:28:43Z
dc.date.issued2016
dc.description.abstractPurpose: To evaluate the efficacy and safety of intravitreal dexamethasone implant in treatmant of macular edema related to retinal vein occlusions. Material and Methods: The charts of 38 patients treated with intravitreal dexamethasone implant due to macular edema related to retinal vein occlusions between 1 May 2013 and 1 September 2014 in Trakya University Ophthalmology Department were retrospectively evaluated. Results: In 23 patients with branch retinal vein occlusion (BRVO), while 15 had central retinal vein occlusion (CRVO). Mean age was 66.47±9.48; 17 men (%44.7) and 21 women (%55.3) patients were available. Postinjection best corrected visual acuity (BCVA) was better than preinjection at each visit in BRVO patients (p0.05). Postinjection central macular thickness (CMT) was thinner than preinjection and statistically significant at postinjection 1 day, 1 week, 1 month, 2 month, 3 month and 6 month (p0.05). BCVA increased statistically significant to preinjection at postinjection 1 week, 1 month and 2 month in CRVO patients (p0.05). BCVA was reduced at postinjection 3 months, gradually increased going from 4 to 6 months also showed no statistically significant difference compared to preinjection (p0.05). CMT decreased incipiently postinjection 1 day to postinjection 2 month and thickness reduction was statistically significant at postinjection 1 day, 1 week, 1month and 2 month (p0.05). Medical therapy was adequate in patients with intraocular pressure rising and one patient underwent cataract surgery. Results: It is shown intravitreal dexamethasone implant is effective and safe in treatment of macular edema related to retinal vein occlusions. © 2015 Gazi Eye Foundation. All rights reserved.en_US
dc.identifier.endpage156en_US
dc.identifier.issn1300-1256
dc.identifier.issue2en_US
dc.identifier.scopus2-s2.0-85062831005en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage151en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/17358
dc.identifier.volume24en_US
dc.indekslendigikaynakScopusen_US
dc.language.isotren_US
dc.publisherGazi Eye Foundationen_US
dc.relation.ispartofRetina-Vitreusen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectIntravitreal Dexamethasone Implant; Macular Edema; Retinal Vein Occlusionen_US
dc.subjectDexamethasone; Aged; Article; Best Corrected Visual Acuity; Branch Retinal Vein Occlusion; Cataract Extraction; Central Macular Thickness; Central Retina Vein Occlusion; Clinical Article; Clinical Effectiveness; Female; Human; Intraocular Pressure; Macular Edema; Male; Retina Vein Occlusionen_US
dc.titleThe effectiveness of intravitreal dexamethasone implant in macular edema related to retinal vein occlusionsen_US
dc.title.alternativeRetina ven tikanikligina bagli makula ödeminde intravitreal deksametazon implantin etkinligien_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu